Glucopyranosyl Derivative and Use Thereof - Sunshine Lake Pharma
Summary
The European Patent Office published patent EP3743412A1 for Sunshine Lake Pharma Co., Ltd. covering glucopyranosyl derivatives and their therapeutic applications. The patent, effective April 1, 2026, designates 37 European member states and covers compounds classified under C07D organic chemistry with pharmaceutical applications including diabetes, metabolic disorders, and cardiovascular conditions.
What changed
The European Patent Office issued patent EP3743412A1 to Sunshine Lake Pharma Co., Ltd. for a glucopyranosyl derivative and its therapeutic applications. The patent covers compounds effective for treating diabetes (A61P3/10), metabolic disorders, cardiovascular conditions, and renal diseases, with protection extending across 37 designated European member states.
For pharmaceutical companies and researchers, this patent represents a blocking intellectual property position in the European market for SGLT2 inhibitor-class glucopyranosyl derivatives. Competitors developing similar compounds for diabetes or metabolic indications should assess freedom-to-operate and potential licensing requirements to avoid infringement in designated EPO territories.
What to do next
- Monitor for potential licensing or partnership opportunities
- Review patent claims for freedom-to-operate implications
- Update IP portfolio tracking databases
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF
Publication EP3743412A1 Kind: A1 Apr 01, 2026
Applicants
Sunshine Lake Pharma Co., Ltd.
Inventors
GU, Zheng, WU, Wuyong, QU, Tong, KANG, Panpan, ZHANG, Zongyuan, HUANG, Weiming, LIU, Jianyu, ZHANG, Yingjun
IPC Classifications
C07D 309/10 20060101AFI20210927BHEP C07H 9/04 20060101ALI20210927BHEP A61K 31/35 20060101ALI20210927BHEP A61K 31/351 20060101ALI20210927BHEP A61P 3/10 20060101ALI20210927BHEP A61P 3/00 20060101ALI20210927BHEP A61P 3/04 20060101ALI20210927BHEP A61P 3/06 20060101ALI20210927BHEP A61P 5/48 20060101ALI20210927BHEP A61P 9/00 20060101ALI20210927BHEP A61P 9/04 20060101ALI20210927BHEP A61P 9/10 20060101ALI20210927BHEP A61P 9/12 20060101ALI20210927BHEP A61P 13/12 20060101ALI20210927BHEP A61P 27/02 20060101ALI20210927BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.